# Starget Pharma Inc. — Form D

Starget Pharma Inc. of SHREVEPORT, LA, a company, filed a Form D exempt-offering notice with the SEC on 2026-02-03. The offering totals $22.2M, of which $16.4M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2026-02-03
- Form: D
- Accession: 0002108969-26-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $22.2M
- Amount sold: $16.4M
- Remaining: $5.8M
- Minimum investment: $50K
- Investors: 29
- Date of first sale: 2026-01-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-572220

## Issuer

- Name: Starget Pharma Inc.
- CIK: 0002108969
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2025
- Address: 2031 KINGS HIGHWAY, SHREVEPORT, LA, 71103
- Phone: 318-746-8430

## Officers, directors & promoters (2)

| Name | Role | Location |
| --- | --- | --- |
| Ronen Kalmanson | Director | Ramat Hasharon, L3 |
| Sigal Kalmanson Cusnir | Executive Officer | Tzofit, L3 |

## More

- [CIK 2108969 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2108969&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0002108969-26-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.